Cigna Corp (CI · NYSE)

Cigna shares have slid 5.0% over the past month and 6.8% over three months to $270.53, leaving the stock 11.0% below its 52-week high with RSI(14) at 28, even as the company beat consensus in all four of its most recent quarters, including $7.78 versus $7.58 estimated for the quarter ended June 30, 2026. Fundamentals show revenue of $71.67B for the latest quarter (up 6.7% YoY on a TTM basis of $282.38B) and earnings growth of 10.2%, with the stock trading at a P/E of 11.18 and EV/EBITDA of 7.64 against an analyst target of $342.29. Leverage stands at 2.5x debt/EBITDA with $31.88B in total debt and $6.30B in cash, though operating cash flow was negative $421.0M in the June quarter, producing free cash flow of negative $718.0M. A recent analysis argued the stock could be 58% undervalued, citing PBM and claims review concerns as a drag on the share price.